<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One of the conclusions of the subcommittee meeting on <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">Anticoagulant</z:chebi>/<z:chebi fb="0" ids="16247">Phospholipid</z:chebi> dependent antibodies, held in Geneva on 2007, was the need to update the guidelines on <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">Anticoagulant</z:chebi> (LA) detection </plain></SENT>
<SENT sid="1" pm="."><plain>Particular emphasis was given to several aspects discussed in this official communication </plain></SENT>
<SENT sid="2" pm="."><plain>A new paragraph is dedicated to the patient selection, and aims to minimize inappropriate requests for LA testing </plain></SENT>
<SENT sid="3" pm="."><plain>Modalities for blood collection and processing are fully delineated and the choice of tests is limited to dRVVT and a sensitive aPTT </plain></SENT>
<SENT sid="4" pm="."><plain>Calculation of cut-off values for each diagnostic step are clearly stated </plain></SENT>
<SENT sid="5" pm="."><plain>A final paragraph reports the interpretation of the results in general and in particular situations </plain></SENT>
</text></document>